Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Roivant First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 69,155,846 | $730,977,292 | -1% | 2.8% |
| 2. | QVT Financial Daniel Gold | 66,719,779 | $705,228,064 | 66.31% | |
| 3. | Rubric Capital Management David Rosen | 23,000,000 | $243,110,000 | +15% | 6.37% |
| 4. | Two Seas Capital Sina Toussi | 10,318,764 | $109,069,335 | +31% | 17.72% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 8,000,939 | $84,569,925 | -29% | 0.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 4,000,000 | Large Shareholder | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | Large Shareholder | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | Large Shareholder | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.92 | 96,950 | 532,207 | 2024-02-09 | Filing | ||
| $11.05 | 3,000,000 | Large Shareholder | 51,929,426 | 2024-01-02 | Filing | |
| $10.11 | 153,027 | 595,397 | 2023-10-05 | Filing | ||
| $10.25 | 606,221 | 595,397 | 2023-10-03 | Filing | ||
| $10.80 | 440,752 | 595,397 | 2023-10-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 73,031,667 | $820,145,620 | 7.29% | |
| 2. | 36,976,248 | $415,243,265 | 0.03% | |
| 3. | 21,927,044 | $246,240,711 | 0.02% | |
| 4. | 20,805,601 | $233,646,898 | 0% | |
| 5. | 13,727,418 | $154,158,904 | 0% |
News See All
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Roivant Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV)
The healthcare industry is considered to be a fairly defensive sector due to its need.
7 Best Mid-Cap Healthcare Stocks To Buy Now
The healthcare industry is considered to be a fairly defensive sector due to its need.
Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1
Greenlight Capital, an investment management firm, released its first quarter 2024 investor letter. A copy of the letter can be downloaded here.
5 Most Undervalued Stocks to Buy for Under $20
In this piece, we will take a look at the five most undervalued stocks to buy that are trading under $20.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
5 Best Biotech Stocks To Buy Under $20
In this article, we are going to take a closer look at five best biotech stocks to buy under $20.
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
Do You Think the Management of Roivant Sciences (ROIV) Can Create Value?
Tourlite Capital Management, an investment management firm, released its fourth quarter 2023 investor letter, a copy of which can be downloaded here.
Billionaire Hedge Funds
